Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Ardelyx (Nasdaq: ARDX) will report full year and fourth quarter 2025 results and host a conference call on Thursday, February 19, 2026 at 4:30 p.m. Eastern Time.

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) will report full year and fourth quarter 2025 results and host a conference call on Thursday, February 19, 2026 at 4:30 p.m. Eastern Time. The call will feature the executive leadership team and include a business update.

Live audio will be webcast via the Investors section at the company's website and archived for replay for 30 days.

Argus Feb 5 session

-5.15% close to close Open Argus

Details

News Market Reaction – ARDX

In the Feb 5 session, ARDX declined 5.15%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.2% in the session following this news. A negative reaction despite this being onl...

Analysis

The stock moved -5.2% in the session following this news. A negative reaction despite this being only an earnings-date announcement would fit a pattern where some positive operational updates, such as the recent patent issuance and Phase 3 trial initiation, coincided with modest declines. With preliminary 2025 revenue of roughly $378 million and 2026 guidance already disclosed, the upcoming February 19, 2026 call may largely confirm prior expectations, leaving sentiment sensitive to any incremental details or changed assumptions.

Key Figures

2025 product revenue: $378 million IBSRELA 2025 revenue: $274 million IBSRELA Q4 2025: $87 million +5 more

2025 product revenue

$378 million

Preliminary unaudited 2025 product revenue

IBSRELA 2025 revenue

$274 million

IBSRELA 2025 revenue, 73% increase vs. 2024

IBSRELA Q4 2025

$87 million

Q4 2025 IBSRELA revenue

XPHOZAH 2025 revenue

$104 million

XPHOZAH full-year 2025 revenue

XPHOZAH Q4 2025

$28 million

Q4 2025 XPHOZAH revenue

Year-end 2025 cash

$265 million

Cash, cash equivalents and investments at end of 2025

2026 IBSRELA guidance

$410–430 million

Expected 2026 IBSRELA revenue

2026 XPHOZAH guidance

$110–120 million

Expected 2026 XPHOZAH revenue

Historical Context

5 past events · Latest: Feb 03

5 events

1. Feb 03

   Patent issuance

   24h Move

   -0.6%

   USPTO issued new tenapanor formulation patent expiring November 26, 2042.

2. Jan 28

   Phase 3 trial start

   24h Move

   -0.4%

   First patient dosed in ACCEL Phase 3 CIC study of IBSRELA (tenapanor).

3. Jan 08

   Prelim 2025 revenue

   24h Move

   +20.1%

   Preliminary 2025 revenue, strong IBSRELA growth and 2026 guidance outlined.

4. Nov 07

   Real-world data

   24h Move

   +1.1%

   Real-world XPHOZAH data showed phosphate reductions and patient satisfaction.

5. Nov 05

   Conference participation

   24h Move

   +6.3%

   Management participation in Jefferies Global Healthcare Conference fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura Williams M.D., M.P.H., Chief Patient Officer and Interim Chief Medical Officer.

To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ardelyx (ARDX) report full year and Q4 2025 financial results?

Ardelyx will report results on February 19, 2026 and host a call at 4:30 p.m. ET. According to Ardelyx, the call covers full year and fourth quarter 2025 financial results and a business update from company leadership.

How can investors join the Ardelyx (ARDX) conference call on February 19, 2026?

Dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and request the Ardelyx call. According to Ardelyx, the live audio will also be simultaneously webcast on the Investors section of the company's website for remote access.

Who will speak on the Ardelyx (ARDX) February 19, 2026 earnings call?

Speakers include CEO Mike Raab, CFO Sue Hohenleitner, CCO Eric Foster, and Chief Patient Officer and Interim CMO Laura Williams M.D., M.P.H. According to Ardelyx, members of the executive leadership team will provide commentary and a business update.

Where will the Ardelyx (ARDX) webcast be available and how long will the replay last?

The live webcast will be available under the Investors section at www.ardelyx.com and archived for replay. According to Ardelyx, the webcast replay will remain accessible for 30 days following the February 19, 2026 call.

What topics will Ardelyx (ARDX) cover during the February 19, 2026 call?

The call will discuss full year and fourth quarter 2025 financial results and provide a business update from leadership. According to Ardelyx, the management team will offer commentary on company performance and operational highlights for investors.